Research programme: neuroprotectants - Cenomed BioSciences

Drug Profile

Research programme: neuroprotectants - Cenomed BioSciences

Alternative Names: Biodefense therapeutics - Cenomed BioSciences LLC; CB-2,501; Chemical defense programme - Cenomed BioSciences LLC; CM-2,501

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cenomed BioSciences LLC
  • Class Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Cholinergic receptor modulators; Imidazoline receptor agonists; Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neurological-disorders(Prevention) in USA
  • 30 Jun 2010 Celgene Corporation to acquire Abraxis BioScience
  • 25 Sep 2007 Cenomed BioSciences LLC establishes CRADA with the United States Army Medical Research Institute of Chemical Defense for the development of CM 2501 and related compounds as biodefense agents
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top